Our research projects

Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.

Finding out which changes to how DNA is read in neuroblastoma can give doctors more information about the cancer, and investigating whether these changes could be stopped through medicines.

Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.

Looking at how medulloblastoma brain tumours use an amino acid, and whether blocking access to that resource would make cancer cells more susceptible to treatment.

Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.

Looking at how nanoparticles could improve drug delivery and reduce toxicity for young cancer patients.

Using two drugs to prevent an essential Wilms tumour protein interacting with a growth-promoting protein, and testing this treatment in patient samples.

Investigating how cancer cells can keep dividing and why this makes it harder to treat.

Testing whether treatment could be safely reduced for children with germinoma brain tumours